Phaseline

Companies › Shin Poong Pharmaceutical

Shin Poong Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 3, 1 Phase 2; Cardiovascular, Gastroenterology, Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SP-8203 (Otaplimastat)
Matrix metalloproteinase inhibitor
–Phase 3Ischemic StrokeMar 2027
Candesartan (SPC1001)
Type-1 angiotensin II receptor antagonist
AGTR1Phase 2Hypertension, Essential; Cardiomyopathy, Dilated; Liver Fibroses–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06826872Candesartan (SPC1001)Phase 2Hypertension, EssentialCardiovascularOct 2025
NCT05321875Candesartan (SPC1001)Phase 3Cardiomyopathy, DilatedCardiovascularJun 2026
NCT06660719SP-8203 (Otaplimastat)Phase 3Ischemic StrokeNeurologyMar 2027
NCT03770936Candesartan (SPC1001)Phase 3Liver FibrosesGastroenterologyNov 2027

Targets

AGTR1 (1)

Companies with the same targets

THPharm HB BioTech Chong Kun Dang Pharmaceutical Yuhan Shenzhen Salubris Pharmaceuticals Travere Therapeutics Chia Tai Tianqing Pharmaceutical Group

Companies built like this

THPharm Shenzhen Salubris Pharmaceuticals Zydus Therapeutics Livzon Pharmaceutical Group CSPC Mingfule Pharmaceutical (Guangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.